| Literature DB >> 32456328 |
Francesca Donnaloja1, Federica Carnevali1, Emanuela Jacchetti1, Manuela Teresa Raimondi1.
Abstract
Mechanotransduction translates forces into biological responses and regulates cell functionalities. It is implicated in several diseases, including laminopathies which are pathologies associated with mutations in lamins and lamin-associated proteins. These pathologies affect muscle, adipose, bone, nerve, and skin cells and range from muscular dystrophies to accelerated aging. Although the exact mechanisms governing laminopathies and gene expression are still not clear, a strong correlation has been found between cell functionality and nuclear behavior. New theories base on the direct effect of external force on the genome, which is indeed sensitive to the force transduced by the nuclear lamina. Nuclear lamina performs two essential functions in mechanotransduction pathway modulating the nuclear stiffness and governing the chromatin remodeling. Indeed, A-type lamin mutation and deregulation has been found to affect the nuclear response, altering several downstream cellular processes such as mitosis, chromatin organization, DNA replication-transcription, and nuclear structural integrity. In this review, we summarize the recent findings on the molecular composition and architecture of the nuclear lamina, its role in healthy cells and disease regulation. We focus on A-type lamins since this protein family is the most involved in mechanotransduction and laminopathies.Entities:
Keywords: Emery-Dreyfuss muscular dystrophy; Hutchinson Gilford progeria syndrome; gene regulation; lamin A/C; lamin partners; laminopathy; mechanotransduction
Mesh:
Substances:
Year: 2020 PMID: 32456328 PMCID: PMC7291067 DOI: 10.3390/cells9051306
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1The general structure of lamins. From top to bottom: single chain structure, dimer organization and tetramer structure. The structural organization of human lamins consists of head, central rod, and C-terminal tail containing the globular Ig-like domains. Dotted lines represent unstructured regions. The central rod domain is divided into the three coiled coil domains C1a, C1b, and C2, separated by the flexible linkers L1 and L12. Two single chains associate with their coiled coil domains to form parallel (polar) homodimers, which bind other identical homodimers via head-to-tail interactions thus forming a polar structure (chain A and chain B). In line with other IF structures, the homodimers interact laterally with other identical homodimers arranged in an antiparallel way. The resulting structure is an antiparallel (apolar) tetrameric filament (chain A, chain B, chain C, and chain D).
Figure 2Prelamin A post-translational modifications during the maturation phase. (a) Cysteine farnesylation of prelamin A at the -CAAX box by Farnesyltransferase enzyme (FTase). (b) Hydrolysis of –aaX motif by either RCE1 or ZMPSTE24 enzyme and C-terminal methylation at terminal cysteine via ICMT. (c) Mature lamin A structure after the cleavage of the last 15 amino acids via ZMPSTE24 enzyme.
Wild type human lamin A/C fragments obtained by X-ray.
| PDB Code | Segment | X-ray Resolution | a.a. | Chain |
|---|---|---|---|---|
| 1X8Y [ | Coil 2B | 2.2 Å | 305–389 | Single chain (A) |
| 3V5B [ | Coil 2B | 3 Å | 313–386 | Single chain (A) |
| 1IFR [ | Globular domain | 1.4 Å | 436–552 | Single chain (A) |
| 2XV5 [ | Coil 2B | 2.4 Å | 328–398 | Dimer (A + B) |
| 6SNZ [ | Coil 1B | 2.6 Å | 65–222 | Tetramer (A + B + C + D) |
| 6JLB [ | Head-coil 2 | 3.2 Å | 1–300 | Tetramer (A + B + C + D) |
The table lists the fragments PDB codes, the corresponding domains, the X-ray resolutions achieved, the amino acids involved, and the name of the solved chains of the A-type lamins.
Wild type human lamin B1 fragments obtained by X-ray.
| PDB Code | Segment | X-ray Resolution | a.a. | Chain |
|---|---|---|---|---|
| 3UMN [ | Globular domain | 2 Å | 428–550 | Trimer (A + B + C) |
| 3TYY [ | Coil 2B | 2.4 Å | 311–388 | Dimer (A + B) |
The table lists the fragments PDB codes, the corresponding domains, the X-ray resolutions achieved, the amino acids involved and the name of the solved chains of the lamin B1.
Figure 3Tetrameric structure of the lamins proposed by Ahn et al. The structure of the polar dimers is reported as a single chain. In this innovative model, both the interactions A11 (C1b domain interaction) and eA22 (C2 domain interaction) are satisfied, while still maintaining the antiparallel layout of the dimers.
Main binding partners of human lamin A/C.
| Binding Partner | Description | A-Type Lamin Binding Region | Reference |
|---|---|---|---|
| Lamin B | Despite their distinct assembly pathways, “the stage is set” for the assembly of A-type lamins. | ND * | [ |
| Nuclear Actin | Essential for the integrity of the nuclear envelope, it mediates chromatin movement during transcription and mitosis. Failure of this binding impairs the role of nuclear actin, as happens in Hutchinson-Gilford Progeria Syndrome (see details in | 461–536 and 564–608 | [ |
| Emerin | Protein of the LEM-domain family; it is relatively immobile in the INM and it anchors the lamina. It also binds directly to the barrier-to-autointegration factor (BAF), retaining chromatin close to the nuclear envelope during cell interphase and acts on gene expression inhibition. Loss of emerin causes Emery-Dreifuss muscular dystrophy (see details in | 384–566 | [ |
| LAP1 | Integral membrane protein that binds both A- and B-type lamins. Its role has not been characterized yet, but it is involved in Primary dystonia, a central nervous system laminopathy caused by a mutation in torsin A. | ND * | [ |
| LAP2α | The most-studied architectural partner for A-type lamins. It is located inside the nucleus and is necessary to maintain lamin A/C in a soluble and low-assembly state. Its binding to transcriptional regulators suggests its influence in gene regulation either directly, or indirectly through the lamins. Mutations in LAP2α which disrupt the binding to the A lamin are known to cause dilated cardiomyopathy. | 319–566 | [ |
| Nesprin 1α | Nuclear membrane protein that directly binds A-type lamins and emerin and anchors them at the nuclear envelope. Human fibroblasts lacking A-type lamins present mis-localized nesprin 1α and emerin (which are located at the endoplasmic reticulum level) inducing an impaired nuclear geometry and peripheral chromatin loss as occurs in Emery-Dreifuss muscular dystrophy. | ND * | [ |
| SUN1/2 | Essential during cell mitosis. Its important role has been recently suggested in anchoring and opening the nuclear pore complex, and therefore, regulating the nuclear influx of transcription factors. | 389–664 | [ |
| SREBP1 a/c | Known to activate genes required for cholesterol biosynthesis and adipocyte differentiation. They bind the Ig-fold domain of A-type lamins. Deregulation of this binding is involved in lipodystrophies. | 389–664 | [ |
| MAN1 | LEM-domain protein; it binds BAF directly, but also DNA. It is involved in TGF-β-signaling, important for bone development. | 394–664 | [ |
| PKCα | Serine/threonine kinase, activated by many signal pathways and involved in lamin phosphorylation. Once activated, it translocates to the nucleus and binds to the A-type lamin tail to trigger post translational modifications. | 500–664 | [ |
| 12(S)-LOX | Lamin binding enzyme 12(S)-lipoxygenase converts arachidonic acid (AA) to 12(S)-hydroxy eicosatetraenoic acid [12(S)-HETE] and is involved in the lipid signaling pathway. It also activates PKCα mediating prostate tumor cell metastasis. | 463–664 | [ |
| cFos | Early response transcription factor sequestrated at the nuclear envelope by A-type lamins. During MAP kinase signaling, this binding is released and c-Fos can facilitate cell proliferation. | 81–219, 243–388 and 453–571 | [ |
| Rb | Transcriptional regulator that has a central role in cell-cycle control and in apoptosis mechanisms. It directly binds to A-type lamins and to LAP2α. It appears that Rb tumor suppressor activity depends on its attachment to both proteins. | 247–355 | [ |
| MOK2 | DNA-binding transcriptional repressor that modulates gene expression activated by the cone-rod homeobox protein (Crx), by competing binding to the same binding sites. It also seems to influence RNA processing. | 243–387 | [ |
| IMPORTIN α | Nuclear import receptor. It is supposed to prevent lamins from assembling in the nucleoplasm. | ND * | [ |
| BAF | Non-specific double-stranded DNA-binding protein. It can bridge DNA and interacts with histones. It also binds several transcription activators including Crx, with an analogous function to MOK2. Alterations in BAF expression lead to impaired chromatin structure, nuclear envelope defects and altered gene expression. | 432–544 | [ |
| LAD | Lamina-associated domains containing lowly transcribed genes. They are dynamic structures involved in chromosomes organization, gene repression, and cell differentiation. LAD disruptions have been correlated to diseases such as Hutchinson Gilford progeria syndrome (see details in | ND * | [ |
| Core histones | Their interaction with A-type lamins affects chromatin localization and gene expression. | 396–430 | [ |
| PCNA | Necessary to activate the DNA replication machinery, it binds to the Ig-fold domain. | 436–552 | [ |
| DNA | The lamin-DNA interaction occurs directly, but non-specifically, by contacting the minor groove. The DNA-binding region is identical in both lamin A and lamin C. Some lamin A mutations drastically reduce the DNA affinity, leading to gene regulation problems. | 411–553 | [ |
* ND = not determined, yet.
Figure 4A-type lamin-binding partners at the nuclear envelope (NE) level. Lamina underlines the nuclear membrane and consists of A-type lamins (in blue) and B-type lamins (in red). Proteins interacting with A-and B-types lamins are schematized and their localization into the cell nucleus. The proteins interacting with lamins at the level of the nuclear envelope are thought to have mainly a mechanical and structural role; proteins bridging directly lamins and chromatin play a key role in reinforcing the nucleoskeleton and in mechanical regulation of gene transcription; others regulate cell signaling.
Figure 5A-type lamin-binding proteins and their known binding site. (Top) a scheme of the pre-lamin A structural domains, schematized in the N-terminal head, the central coiled-coil region (including the coil 1A, coil 1B and coil 2 shown in the previous figures), and the C-terminal tail including the Ig-fold domain. The residues bar indicates the positions of the respective amino acids. The amino acids after residue 646 are normally removed by proteolytic cleavage to generate mature lamin A. Lamin C is identical to lamin A till residue 566 and contains 6 lamin C-specific amino acids at its C-terminus. (Bottom) List of A-types lamin binding proteins and their relating binding sites.
Figure 6The role of lamina in mechanotransduction. Starting from the extracellular matrix, integrins transmit the external impulse to the cytoskeleton (A), which then transfers the stimulus to the lamina structure (B). The lamins first act as a mechanosensor and rearrange their molecular structures (D), hiding the sites for phosphorylation (F). The inhibited phosphorylation activity increases the amount of lamins at the nuclear envelope with a consequent increase in lamina stiffness (J). At this level, the lamina mesh guarantees the nuclear protection (N) and higher stress sensitivity (O), which impact on the rearrangement of the lamina (S) and affect cell motility (P). Lamina rearrangement is correlated to the higher nuclear localization of some transcription factors (K), whose activity is also enhanced by the alteration in chromatin structure (C). The rearrangement of the lamina leads to a reorganization of the chromatin (C), thus altering the sites available to the transcription factors (E) for lamins (G), cytoskeleton (H), and differentiation genes (I). The reorganization of the chromatin sites and the higher nuclear availability of transcription factors alter the transcription of the lamins (M,G) which thus provides feedback on the lamina stiffness (Q). The chromatin reorganization also acts on the transcription of the cytoskeleton components (H), which in turn affects the force transmission to the lamina at the upstream level (R). To conclude, the chromatin reorganization affects the differentiation gene transcription (I), which, combined with the increased transcription factor nuclear localization (L), act on cell differentiation activity (T). Orange is used to highlight the key position of the lamina at the crossroads of the mechanotransduction pathway, and green highlights all the revealed downstream effects of the lamina reorganization. Green arrows represent the lamins feedback loop.
Figure 7Stable conformations of the lamin dimers. (a) Lamin dimers in semi-relaxed configuration (total length about 50 nm). (b) The rod of lamin dimers can compress via three sequential tandem staggering of linkers L1, L12, and L3 (total length about 40 nm) for electrostatic interactions.
Figure 8The single-point mutations of the LMNA gene. (a) List of LMNA gene mutations graphically associated with distinct lamin domains. Red indicates the gene mutations related to the following myopathies: EDMD2 (*), EDMD3 (**) LGMD1B (***), CMD (****), AS-SMA (*****), CDM1A (°) and DCM-CD (°°); mutations associated with various uncategorized phenotypes of muscular dystrophy, as reported by Dialynas et al. [182] are also reported in red (°°°). In green, those regarding lipodystrophies: FPLD2 (*) and MS (**). In yellow, the mutations causing the CMT2B1 neuropathy. Finally, blue indicates the gene mutations relative to systemic and premature aging disease: HGPS (*), WRN (**), RD (***), MADA (****), HHS (*****). (b) The percentages for each group of laminopathies. Almost 74% of the single-point mutations cause myopathies. Premature aging and lipodystrophy are 15% and 11%, respectively. Only one mutation has been associated with neuropathy. (c) The percentages for each lamin domain. Ig-fold domain, C2 and C1b involve most of the known mutations, representing 27%, 21%, and 21% of the entire set of mutations, respectively. They are followed by C1a (10%), tail (9%), the domain between C2 and Ig-fold (C2-Ig) (5%), the head (4%), and finally L12 (3%). No mutations have been correlated with L1. (d) Table collecting the percentages related to the mutations classified according to both the domain and the group of laminopathies.
Classification of laminopathies.
| Group | Pathology | OMIM Code | Gene Involved | Reference |
|---|---|---|---|---|
| 1 | Emery-Dreifuss muscular dystrophy, autosomal dominant (EDMD2) | 181350 |
| [ |
| 1 | Emery-Dreifuss muscular dystrophy, autosomal recessive (EDMD3) | 616516 |
| [ |
| 1 | Limb-girdle muscular dystrophy, type 1B (LGMD1B) | 159001 |
| [ |
| 1 | Congenital muscular dystrophy (CMD) | 613205 |
| [ |
| 1 | Autosomal dominant spinal muscular atrophy (AD-SMA) | 182980 |
| [ |
| 1 | Dilated cardiomyopathy 1A (CMD1A) | 115200 |
| [ |
| 1 | Dilated cardiomyopathy with conduction system defects (DCM-CD) | n/a |
| [ |
| 2 | Dunnigan-type familial partial lipodystrophy (FPLD2) | 151660 |
| [ |
| 2 | Metabolic syndrome (MS) | n/a |
| [ |
| 2 | Barraquer-Simons syndrome (acquired partial lipodystrophy -APL) | 608709 |
| [ |
| 3 | Charcot-Marie-Tooth disease, type 2B1 (CMT2B1) | 605588 |
| [ |
| 3 | Autosomal dominant leukodystrophy (ADLD) | 169500 | [ | |
| 4 | Hutchinson-Gilford progeria syndrome (HGPS) | 176670 | [ | |
| 4 | Atypical Werner syndrome (WRN) | 277700 |
| [ |
| 4 | Restrictive dermopathy (RD) | 275210 |
| [ |
| 4 | Mandibuloacral dysplasia with type A lipodystrophy (MADA) | 248370 |
| [ |
| 4 | Heart-hand syndrome, Slovenian type (HHS) | 610140 |
| [ |
Laminopathies subdivided in four groups: myopathies (1), lipodystrophies (2), neuropathies (3), and systemic diseases (4). Figure 8 shows all the specific mutations of the LMNA gene for each pathology (here omitted for the sake of clarity).